4-氨基-4-苯基丁酸 | 1011-60-5

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-氨基-4-苯基丁酸
• 英文名称: DL-4-Phenyl-4-aminobuttersaeure
• 英文别名: (rac)-4-amino-4-phenylbutanoic acid；4-Amino-4-phenyl-buttersaeure；DL-4-Amino-4-phenylbuttersaeure；DL-γ-Amino-γ-phenyl-n-buttersaeure；γ-Amino-γ-phenyl-buttersaeure；R.S-4-Amino-4-phenyl-buttersaeure；4-amino-4-phenyl-butyric acid；4-azaniumyl-4-phenylbutanoate
• CAS: 1011-60-5
• 化学式: C₁₀H₁₃NO₂
• 分子量: 179.219
• InChiKey: QCHLDIVWWGHNQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  5-苯基-2-吡咯烷酮	(+/-)-5-phenyl-2-pyrrolidinone	22050-10-8	C10H11NO	161.203
  3-苯丙烯溴酸酯	succinylbenzene	2051-95-8	C10H10O3	178.188

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	(R)-4-amino-4-phenylbutanoic acid	——	C10H13NO2	179.219
  ——	(S)-4-amino-4-phenylbutanoic acid	——	C10H13NO2	179.219
  5-苯基-2-吡咯烷酮	(+/-)-5-phenyl-2-pyrrolidinone	22050-10-8	C10H11NO	161.203
  3-苯丙烯溴酸酯	succinylbenzene	2051-95-8	C10H10O3	178.188

反应信息

• 作为反应物：
  描述：

  4-氨基-4-苯基丁酸 在 氢氧化钾 、 四丁基溴化铵 、 2-氯-1-甲基吡啶碘化物 、 溶剂黄146 、 三乙胺 、 copper(l) chloride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙腈 为溶剂， 反应 20.0h， 生成 5-Phenyl-1-(4-pyrrolidin-1-ylbut-2-ynyl)pyrrolidin-2-one
  参考文献：
  名称：

  Phenyl-substituted analogs of oxotremorine as muscarinic antagonists

  摘要：

  A series of phenyl-substituted analogues of the muscarinic agent oxotremorine (1) have been prepared. The new compounds (3b-11b and 9c) were assayed for antimuscarinic activity on the isolated guinea pig ileum and in intact mice. They were also evaluated for ability to inhibit the binding of the muscarinic antagonist (-)-[H-3]-N-methylscopolamine to homogenates of the rat cerebral cortex. The phenyl-substituted derivatives were devoid of intrinsic muscarinic activity. Instead, they behaved as competitive muscarinic antagonists in these assays with similar or lower affinity for muscarinic receptors than the corresponding methyl-substituted analogues. The succinimide (8b) and the pyrrolidone (3b) derivatives of 1 substituted with a phenyl group at position 1 of the butynyl chain showed the highest antimuscarinic potency with dissociation constants (K(D)) of 0.10 and 0.20-mu-M, respectively, in the ileum assay. The phenyl-substituted analogues showed an approximately 10-fold lower in vivo antimuscarinic potency than their corresponding methyl-substituted positional isomers. A correlation was observed between in vitro and in vivo potency within subsets consisting of methyl- and phenyl-substituted derivatives.

  DOI：

  10.1021/jm00080a013
• 作为产物：
  描述：

  3-苯丙烯溴酸酯 在 [pentamethylcyclopentadienyl*Ir(N-phenyl-2-pyridinecarboxamidate)Cl] 、 甲酸铵 作用下， 以 甲醇 为溶剂， 反应 6.0h， 以95.5%的产率得到4-氨基-4-苯基丁酸
  参考文献：
  名称：

  半夹心铱配合物在温和反应条件下催化还原胺化的范围和局限性。

  摘要：

  使用甲酸铵作为氮源和氢化物源的半夹心铱配合物可以促进醛和酮向 1°胺的转化。为了优化这种绿色化学合成方法，我们在生理温度 (37 °C) 和环境压力下在常见极性溶剂中测试了各种羰基底物。我们发现，在甲醇中，对于广泛种类的含羰基化合物，可以实现胺对醇/酰胺产物的优异选择性。在水性介质中，在不存在酸的情况下，羰基化合物选择性还原为 1° 胺。不幸的是，在水中 Ir 催化剂浓度 <1 mM 时，还原胺化效率显着下降，

  DOI：

  10.1016/j.tetlet.2020.152196

文献信息

• Amino acid derived prodrugs of propofol, compositions and uses thereof
  申请人：Gallop A. Mark

  公开号：US20050004381A1

  公开（公告）日：2005-01-06

  The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.

  本发明提供了丙泊酚前药、制备丙泊酚前药的方法、丙泊酚前药的药物组合物以及使用丙泊酚前药和药物组合物治疗或预防偏头痛疼痛、化疗后或手术后恶心和呕吐等疾病或失调的方法。
• [EN] AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF<br/>[FR] PROMEDICAMENTS DE PROPOFOL DERIVES D'ACIDES AMINES, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
  申请人：XENOPORT INC

  公开号：WO2006017352A1

  公开（公告）日：2006-02-16

  The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post?chemotherapy or post?operative surgery nausea and vomiting.

  本发明提供了丙泊酚前药、制备丙泊酚前药的方法、丙泊酚前药的药物组合物以及使用丙泊酚前药和药物组合物治疗或预防偏头痛疼痛以及化疗后或手术后恶心和呕吐等疾病或失调的方法。
• Enzymatic synthesis of chiral γ-amino acids using ω-transaminase
  作者：Minsu Shon、Ramachandran Shanmugavel、Giyoung Shin、Sam Mathew、Sang-Hyeup Lee、Hyungdon Yun

  DOI：10.1039/c3cc44864a

  日期：——

  In this study, we successfully synthesized enantiomerically pure (R)- and (S)-γ-amino acids (>99% ee) using ω-transaminase (ω-TA) through kinetic resolution and asymmetric synthesis respectively. The present study demonstrates the high potentiality of ω-TA reaction for the production of chiral γ-amino acids.

  在本项研究中，我们通过动力学拆分和对映体合成分别成功合成了纯度很高的（R）-和（S）-γ-氨基酸（>99% ee），这些产物是通过ξ-转氨酶（ξ-TA）实现的。本研究展示了ξ-TA反应在生产手性γ-氨基酸方面的高度潜力。
• Inhibitors of interleukin-1beta converting enzyme
  申请人：Batchelor James Mark

  公开号：US20050143436A1

  公开（公告）日：2005-06-30

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

  本发明涉及一类新型化合物，这些化合物是白细胞介素-1β转化酶的抑制剂。本发明的ICE抑制剂具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可以有利地用作对抗IL-1、凋亡、IGIF和IFN-γ介导的疾病、炎症性疾病、自身免疫疾病、破坏性骨疾病、增生性疾病、传染性疾病、退行性疾病和坏死性疾病的药剂。本发明还涉及抑制ICE活性的方法，用于治疗白细胞介素-1、凋亡、IGIF和IFN-γ介导的疾病，以及使用本发明的化合物和组合物减少IGIF和IFN-γ的产生的方法。本发明还涉及制备N-酰氨基化合物的方法。
• beta-sheet mimetics and composition and methods relating thereto
  申请人：Myriad Pharmaceuticals, Inc.

  公开号：US20040014763A1

  公开（公告）日：2004-01-22

  Compounds having the following structure: 1 including pharmaceutically acceptable salts and stereoisomers thereof, wherein A, A′, B, X, Y, R 2 , R 3 , R 4 and R 5 are as defined herein. Such compounds have utility over a wide range of applications, including use as diagnostic and therapeutic agents. In particular, compounds of this invention, and pharmaceutical compositions containing such compounds, are tryptase antagonists.

  具有以下结构的化合物：1，包括药用可接受的盐及其立体异构体，其中A、A'、B、X、Y、R2、R3、R4和R5如本文所定义。这些化合物在广泛的应用范围内具有实用性，包括用作诊断和治疗剂。特别是，本发明的化合物和含有这些化合物的药物组合物是色胺酸蛋白酶抑制剂。